Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01143194 · ClinicalTrials.gov registry record · Phase 1
A Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Effects of Three Doses of the Dietary Supplement oréVida™ on Alertness, Attention and Concentration in Healthy Men and Women
A Phase 1 study, sponsored by dsm-firmenich Switzerland.
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
NCT01143194 is a Phase 1 study that has completed, run by dsm-firmenich Switzerland. The registered enrollment target is 44 participants.
The verdict
NCT01143194, a Phase 1 study, has completed, sponsored by dsm-firmenich Switzerland.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the effects of the dietary supplement oréVida™ (active ingredient on the basis of a culinary herb)administered twice daily in an acute study on an improvement in vigilance, attention, concentration, memory and mood in 45 healthy men and pre-menopausal women, aged 35-50 years, inclusive. oréVida™ is considered a dietary supplement, and therefore it is not an approved drug by the Food and Drug Administration (FDA). It is regulated like a food. The U.S. Food and Drug Administration does not strictly regulate herbs and dietary supplements. We do not claim that this supplement is meant to treat any ailment.
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT oréVida™
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2010-03 |
| Est. Completion | 2010-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01143194
The ClinicalTrials.gov registry entry for NCT01143194 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is dsm-firmenich Switzerland, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01143194 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01143194 about?
NCT01143194 is a clinical study titled "A Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Effects of Three Doses of the Dietary Supplement oréVida™ on Alertness, Attention and Concentration in Healthy Men and Women". The purpose of this study is to investigate the effects of the dietary supplement oréVida™ (active ingredient on the basis of a culinary herb)administered twice daily in an acute study on an improvement in vigilance, attention, concentration, memory and mood in 45 healthy men and pre-menopausal wome...
What is the current status of trial NCT01143194?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2010-03. Estimated completion is 2010-11.
What interventions are being tested in trial NCT01143194?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), oréVida™ (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01143194?
This trial is sponsored by dsm-firmenich Switzerland, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.